Renaissance Technologies (RenTech)'s RCUS Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 32,700 shares of Arcus Biosciences, Inc. (RCUS) worth $779,241, representing 0.00% of the portfolio. First purchased in 2019-Q2, this medium-term investment has been held for 18 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in RCUS, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2021, adding 256,900 shares. Largest reduction occurred in Q3 2021, reducing 275,700 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Arcus Biosciences (RCUS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Arcus Biosciences (RCUS) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -186,600 | Reduce 85.09% | 32,700 | $23.83 |
| Q3 2025 | -148,800 | Reduce 40.42% | 219,300 | $13.60 |
| Q2 2025 | +164,100 | Add 80.44% | 368,100 | $8.14 |
| Q1 2025 | +185,500 | Add 1002.70% | 204,000 | $7.85 |
| Q4 2024 | -165,400 | Reduce 89.94% | 18,500 | $14.89 |
| Q3 2024 | +101,500 | Add 123.18% | 183,900 | $15.29 |
| Q2 2024 | -158,100 | Reduce 65.74% | 82,400 | $15.23 |
| Q1 2024 | +117,000 | Add 94.74% | 240,500 | $18.88 |
| Q4 2023 | -19,300 | Reduce 13.52% | 123,500 | $19.10 |
| Q3 2023 | +142,800 | New Buy | 142,800 | $17.95 |
| Q3 2021 | -275,700 | Sold Out | 0 | $0.00 |
| Q2 2021 | +18,800 | Add 7.32% | 275,700 | $27.46 |
| Q1 2021 | +256,900 | New Buy | 256,900 | $28.08 |
| Q2 2020 | -261,416 | Sold Out | 0 | $0.00 |
| Q1 2020 | +44,178 | Add 20.34% | 261,416 | $13.88 |
| Q4 2019 | +76,400 | Add 54.25% | 217,238 | $10.10 |
| Q3 2019 | +106,238 | Add 307.05% | 140,838 | $9.10 |
| Q2 2019 | +34,600 | New Buy | 34,600 | $7.95 |
Renaissance Technologies (RenTech)'s Arcus Biosciences Investment FAQs
Renaissance Technologies (RenTech) first purchased Arcus Biosciences, Inc. (RCUS) in Q2 2019, acquiring 34,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Arcus Biosciences, Inc. (RCUS) for 18 quarters since Q2 2019.
Renaissance Technologies (RenTech)'s largest addition to Arcus Biosciences, Inc. (RCUS) was in Q1 2021, adding 256,900 shares worth $7.21 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 32,700 shares of Arcus Biosciences, Inc. (RCUS), valued at approximately $779,241.
As of the Q4 2025 filing, Arcus Biosciences, Inc. (RCUS) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Arcus Biosciences, Inc. (RCUS) was 368,100 shares, as reported at the end of Q2 2025.